Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/19/2018 06/20/2018 06/21/2018 06/22/2018 06/25/2018 Date
73.28(c) 74.02(c) 73.44(c) 74.64(c) 73.44 Last
6 344 531 5 223 596 4 057 275 3 523 008 2 149 468 Volume
-0.60% +1.01% -0.78% +1.63% -1.61% Change
More quotes
Financials (USD)
Sales 2018 52 590 M
EBIT 2018 13 229 M
Net income 2018 10 415 M
Debt 2018 13 548 M
Yield 2018 3,93%
Sales 2019 54 174 M
EBIT 2019 14 025 M
Net income 2019 10 481 M
Debt 2019 11 450 M
Yield 2019 4,07%
P/E ratio 2018 15,65
P/E ratio 2019 18,56
EV / Sales2018 3,91x
EV / Sales2019 3,76x
Capitalization 192 B
More Financials
Company
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products.It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate.The Innovative Medicines segment researches, develops, manufactures, distributes and... 
Sector
Pharmaceuticals
Calendar
07/18Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
06/21FINDINGS IN ATOPIC DERMATITIS REPORT : Results of a real-world study)
AQ
06/21NOVARTIS : New Multiple Myeloma Findings Reported from Novartis [Pre-clinical va..
AQ
06/21NOVARTIS : JULIET trial of Kymriah demonstrates more than one-year durability of..
AQ
06/20GLOBAL CARCINOID SYNDROME MANAGEMENT : The research provide Industry Overview, M..
AQ
06/20NOVARTIS : survey uncovers real-world impact of immune thrombocytopenia or ITP, ..
AQ
06/20NOVARTIS : study of real-world data concludes Jakavi is associated with a reduct..
AQ
06/20NOVARTIS : Sandoz presents new long-term and switching data for biosimilars Zess..
AQ
06/19Payers, drugmakers face off over CAR T Medicare coverage
AQ
06/18NOVARTIS : JULIET Trial of Kymriah Demonstrates More Than One-Year Durability of..
AQ
06/18NOVARTIS INTERNATIONAL AG : Alcon AcrySof IQ PanOptix Trifocal Intraocular Lens ..
AQ
More news
Sector news : Pharmaceuticals - NEC
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS 
NOVARTIS - 04/30
Underpinned by a support level
BUY
NOVARTIS AG - 2016
A trend reversal can be anticipated
BUY
More Strategies
Latest Tweets
06/23#4 Roche bags full control of Foundation Medicine in $2.4B follow-up buyout @..
2
06/23Tesaro stock rockets as rumours of Roche takeover abound: At the time of writ.. 
06/23Michael Mendoza-Roche & Alex Fernandez, both 23, charged by w/murder &am.. 
06/22Top 3 today --#1 In high-level reshuffle, Roche gives James Sabry the global .. 
06/22Roche to Close NimbleGen Site, Lay Off 79 by Mid-2020  
More tweets
Qtime:363
News from SeekingAlpha
06/24WEEK IN REVIEW : CITIC Offers $3.6 Billion To Acquire China Biologic 
06/243 THINGS IN BIOTECH, JUNE 23 : Regeneron Spiders Out With Inovio, Synairgen Prov.. 
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/21Forty Seven Readies $100 Million U.S. IPO 
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 90,1 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-9.42%191 991
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.22%213 568
ROCHE HOLDING LTD.-10.81%191 785
MERCK AND COMPANY9.24%165 373
AMGEN6.47%122 515